Cargando…

Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review

BACKGROUND: Diagnosis of metastatic castrate resistant prostate cancer (mCRPC) with current biomarkers is difficult and often results in unnecessary invasive procedures as well as over-diagnosis and over-treatment. There are a number of prognostic biomarkers for CRPC, but there are no validated pred...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Shengri, Lei, Zhen, Gong, Zuo, Sun, Zhonghai, Xu, Dongyuan, Piao, Minhu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448351/ https://www.ncbi.nlm.nih.gov/pubmed/32863768 http://dx.doi.org/10.1186/s12935-020-01508-0

Ejemplares similares

Prognostic value of maximum standard uptake value, metabolic tumor volume, and total lesion glycolysis of (18)F-FDG PET/CT in patients with renal carcinoma: A protocol for systematic review and meta analysis
por: Xuan, Dongchun, et al.
Publicado: (2020)

Protective effect of salidroside on streptozotocin-induced diabetic nephropathy by inhibiting oxidative stress and inflammation in rats via the Akt/GSK-3β signalling pathway
por: Pei, Delong, et al.
Publicado: (2022)

New Prognostic Biomarkers in Metastatic Castration-Resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2021)

Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer
por: De Laere, Bram, et al.
Publicado: (2021)

Biomarker Development Trial of Satraplatin in Patients with Metastatic Castration-Resistant Prostate Cancer
por: Liaw, Bobby C, et al.
Publicado: (2022)

Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer
por: Yun, Seok Joong, et al.
Publicado: (2017)

The prognostic implication of intraductal carcinoma of the prostate in metastatic castration-resistant prostate cancer and its potential predictive value in those treated with docetaxel or abiraterone as first-line therapy
por: Zhao, Jinge, et al.
Publicado: (2017)

Chromogranin A: a useful biomarker in castration-resistant prostate cancer
por: Ploussard, Guillaume, et al.
Publicado: (2022)

Prognostic role of chromogranin A in castration-resistant prostate cancer: a meta-analysis
por: Hong, Peng, et al.
Publicado: (2018)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Prognostic value of testosterone for the castration-resistant prostate cancer patients: a systematic review and meta-analysis
por: Miura, Noriyoshi, et al.
Publicado: (2020)

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
por: Belderbos, Bodine P.S., et al.
Publicado: (2017)

Whole blood GRHL2 expression as a prognostic biomarker in metastatic hormone-sensitive and castration-resistant prostate cancer
por: Kwan, Edmond M., et al.
Publicado: (2021)

Ferroptosis-Related Prognostic Gene LAMP2 Is a Potential Biomarker Differential Expressed in Castration Resistant Prostate Cancer
por: Sun, Chuanyu, et al.
Publicado: (2023)

A robust blood gene expression-based prognostic model for castration-resistant prostate cancer
por: Wang, Li, et al.
Publicado: (2015)

Neutrophil–lymphocyte ratio is prognostic but not predictive of response to Abiraterone in metastatic castration-resistant prostate cancer
por: Sundar, Santhanam, et al.
Publicado: (2015)

Therapeutic Implications for Intrinsic Phenotype Classification of Metastatic Castration-Resistant Prostate Cancer
por: Coleman, Ilsa M., et al.
Publicado: (2022)

FGFR1, a novel biomarker for metastatic castration-resistant prostate cancer?
por: Gallo, Leandro H.
Publicado: (2021)

Biomarkers for Predicting Abiraterone Treatment Outcome and Selecting Alternative Therapies in Castration‐Resistant Prostate Cancer
por: Qin, Sisi, et al.
Publicado: (2022)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer
por: Iwamoto, Hiroaki, et al.
Publicado: (2022)

Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer
por: Sidhu, Amanjot, et al.
Publicado: (2023)

Oncological Response and Predictive Biomarkers for the Checkpoint Inhibitors in Castration-Resistant Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis
por: Fahmy, Omar, et al.
Publicado: (2021)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

A correlative biomarker study and integrative prognostic model in chemotherapy‐naïve metastatic castration‐resistant prostate cancer treated with enzalutamide
por: Fernandez‐Perez, María P., et al.
Publicado: (2022)

Prognostic Value of Body Mass Index in Korean Patients with Castration-Resistant Prostate Cancer
por: Park, Jeong Min, et al.
Publicado: (2012)

Prognostic factors in Japanese men with high-Gleason metastatic castration-resistant prostate cancer
por: Nishimoto, Mitsuhisa, et al.
Publicado: (2022)

Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer
por: Orea, María J., et al.
Publicado: (2023)

The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer
por: Prensner, John R., et al.
Publicado: (2014)

Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management
por: Kessel, Katharina, et al.
Publicado: (2021)

Plasma miRNAs as Biomarkers to Identify Patients with Castration-Resistant Metastatic Prostate Cancer
por: Watahiki, Akira, et al.
Publicado: (2013)

Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer
por: Lin, Hui-Ming, et al.
Publicado: (2017)

Serum N-glycan profiling is a potential biomarker for castration-resistant prostate cancer
por: Matsumoto, Teppei, et al.
Publicado: (2019)

MicroRNAs as Potential Liquid Biopsy Biomarker for Patients with Castration-Resistant Prostate Cancer
por: Fernandez, Nicolas, et al.
Publicado: (2022)

Identification of DNA damage response-related genes as biomarkers for castration-resistant prostate cancer
por: Oshima, Masashi, et al.
Publicado: (2023)

Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer
por: Hwang, Clara, et al.
Publicado: (2023)

Prognostic value of ECOG performance status and Gleason score in the survival of castration-resistant prostate cancer: a systematic review
por: Chen, Wen-Jun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7k8kb1bhhgfh76rhrldm1qo1ot